SLPI Antikörper (Center)

Produktnummer ABIN500774

Produktdetails anti-SLPI Antikörper

Target: SLPI (Secretory Leukocyte Peptidase Inhibitor (SLPI))

Bindungsspezifität: Center

Reaktivität: Human, Maus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser SLPI Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA)

Spezifität: This antibody detects Antileukoproteinase (ALP).

Kreuzreaktivität (Details): Species reactivity (tested):Human, mouse

Aufreinigung: Peptide affinity chromatography

Immunogen: SLPI antibody was raised against a 17 amino acid peptide from near the center of human SLPI.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: ELISA. Western blot: 0.5 - 1 μg/mL. Immunohistochemistry on paraffin sections.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: PBS containing 0.02 % sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freezing and thawing.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store at 2 - 8 °C for up to one month or (in aliquots) at -20 °C for longer.

Referenzen für anti-SLPI Antikörper (ABIN500774)

Sayers, Brooks, Sayers, Chertov: "Increased secretory leukocyte protease inhibitor (SLPI) production by highly metastatic mouse breast cancer cells." in: PLoS ONE, Vol. 9, Issue 8, pp. e104223, (2015) (PubMed).

Details zu SLPI

Target: SLPI (Secretory Leukocyte Peptidase Inhibitor (SLPI))

Andere Bezeichnung: Antileukoproteinase (ALP) (SLPI Produkte)

Synonyme: ALK1 antikoerper, ALP antikoerper, BLPI antikoerper, HUSI antikoerper, HUSI-I antikoerper, MPI antikoerper, WAP4 antikoerper, WFDC4 antikoerper, MATN4 antikoerper, SLPI antikoerper, ckpi antikoerper, secretory leukocyte peptidase inhibitor antikoerper, antileukoproteinase antikoerper, SLPI antikoerper, Slpi antikoerper, LOC102174044 antikoerper

Hintergrund: Secretory leukocyte protease inhibitor (SLPI) is produced at mucosal surfaces, primarily the upper respiratory tract and is thought to play an important role in the antiprotease defense mechanism of the lung. SLPI forms inhibitory complexes with numerous proteolytic enzymes such as neutrophil elastase, and has been shown to possess anti-inflammatory, anti-viral, and antibacterial activities. Its expression in oral epithelial cells is stimulated by HIV-1 gp120, suggesting that SLPI is a component of the oral mucosal response to HIV-1. In peripheral blood monocytes, SLPI can inhibit NF-kB activation by inhibiting IkB degradation in the cytoplasm and competing for NF-kB binding sites in the nucleus. This attenuation of the inflammatory response may also act to suppress liver metastases and other cancer cell invasions, but promote blood-borne metastasis via an invasion-independent pathway.Synonyms: BLPI, HUSI-1, Mucus proteinase inhibitor, Protease inhibitor WAP4, SLPI, Secretory leukocyte protease inhibitor, Seminal proteinase inhibitor, WAP four-disulfide core domain protein 4, WAP4, WFDC4

Gen-ID: 6590

UniProt: P03973